Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials
DOI:
https://doi.org/10.25251/t1b8ft53Keywords:
psoriasis, biologics, trials, PASI, speed of responseAbstract
Background: Biologic therapies targeting interleukin-17 (IL-17) and interleukin-23 (IL-23) pathways have transformed psoriasis management, with IL-17 inhibitors widely regarded as achieving faster clearance. However, the clinical significance of differences in clearance times remains unclear.
Objective: To compare time to achieve a 75% reduction in the Psoriasis Area and Severity Index (PASI75) between IL-17 and IL-23 inhibitors using data from head-to-head clinical trials.
Methods: A PubMed search identified trials reporting PASI75 response times for IL-17 and IL-23 inhibitors. Graphs from 12 studies were analyzed using Engauge Digitizer Software to estimate the time until half of participants reached PASI75.
Results: IL-17 inhibitors achieved PASI75 faster than IL-23 inhibitors, with average response times of 4.5 weeks versus 7 weeks, respectively. The fastest IL-17 agent (bimekizumab) reached PASI75 in 2.5 weeks, while the fastest IL-23 agent (risankizumab) required 5.5 weeks. Differences between classes were smaller than anticipated, particularly for newer IL-23 inhibitors targeting the p19 subunit. Limitations: PASI75 timepoints were estimated from published graphs, introducing potential measurement error.
Conclusion: IL-17 inhibitors generally achieve faster psoriasis clearance than IL-23 inhibitors, but the clinical relevance of this difference is limited. Safety and long-term efficacy profiles should guide treatment selection, highlighting the importance of personalized patient care.
References
1. Johnson MC, Heron CE, Ghamrawi RI, Balogh EA, Feldman SR. Speed of psoriasis treatment response for biologic agents: A review of phase III clinical trials. Journal of Psoriasis and Psoriatic Arthritis. 2021;6(2):99-105. doi:10.1177/2475530321999087
2. Pfau C, Lovell KK, Feldman SR, Extrapolating the Speed of Psoriasis Clearance: A Comparative Analysis of Biologic Agents in Clinical Trials, Journal of the American Academy of Dermatology (2024), doi: https://doi.org/10.1016/j.jaad.2024.06.103.
3. Warren RB, Gooderham M, Burge R, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138-1149. doi:10.1016/j.jaad.2019.12.038
4. Yang, Kevin et al. “Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.” American journal of clinical dermatology vol. 22,2 (2021): 173-192. doi:10.1007/s40257-020-00578-0
5. Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag. 2010 Apr 15;6:123-41. doi: 10.2147/tcrm.s5599. PMID: 20421912; PMCID: PMC2857612.
6. Armstrong AW, Puig L, Joshi A, et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis . JAMA Dermatol. 2020;156(3):258–269. doi:10.1001/jamadermatol.2019.4029
7. Armstrong AW, Merola JF. Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics? J Rheumatol. 2023;50(Suppl 2)
8. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318-1328. doi:10.1056/NEJMoa1503824
9. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial [published correction appears in Lancet. 2021 Feb 20;397(10275):670. doi: 10.1016/S0140-6736(21)00387-1]. Lancet. 2021;397(10273):487-498. doi:10.1016/S0140-6736(21)00125-2
10. Bagel J, Blauvelt A, Nia J, et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol. 2021;35(1):135-142. doi:10.1111/jdv.16558
11. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400-409. doi:10.1016/j.jaad.2015.05.013
12. Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50-59. doi:10.1111/bjd.19341
13. Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047-1058. doi:10.1111/bjd.19509
14. Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014-1023. doi:10.1111/bjd.15666
15. Papp K, Warren RB, Green L, et al. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. Lancet Rheumatol. 2023;5(9):e542-e552. doi:10.1016/S2665-9913(23)00120-0
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Creighton Pfau, Katie K Lovell, Hanna Ozbeki, Steven R. Feldman (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
